Patient enrollment is underway for a clinical trial in which the safety and efficacy of Cosela (trilaciclib) will be assessed in individuals receiving first- or second-line gemcitabine and carboplatin chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer, according to the agent’s manufacturer, G1 Therapeutics.

The study is expected to include two groups of patients; one of which is anticipated to include 170 PD-1/PD-L1 naive patients receiving first-line treatment. The other group is expected to comprise 80 PD-L1 positive patients receiving second-line therapy following previous treatment with PD-1/PD-L1 inhibitors.

Measuring the effect of Cosela on overall survival compared to placebo in patients receiving front-line gemcitabine and carboplatin is the main goal of evaluating the first group. The assessment of the second group is to evaluate the therapy’s effect on overall survival in those receiving the chemotherapy combo as a second-line treatment in patients who already received PD-1/PD-L1 inhibitors.

“Gemcitabine (and) carboplatin has historically been one of the standard first-line regimens for patients undergoing chemotherapy for (metastatic triple-negative breast cancer),” said Dr. Joyce O'Shaughnessy, chair of breast cancer research at Baylor University Medical Center, in a news release. “In a phase 2 study, when (Cosela) was administered prior to this regimen, it enhanced antitumor efficacy compared to gemcitabine/carboplatin alone and improved overall survival with statistical significance. This is an important finding for patients with (metastatic triple-negative breast cancer), and for physicians who treat them.”

Medivir AB recently announced details of a planned clinical trial of one of its investigational drugs — MIV-818 — in patients with hepatocellular carcinoma whose disease progressed on, or was intolerant to, first-line standard treatment.

The plan, according to a news release from the manufacturer, is to assess MIV-818 in two groups of patients. The first group would receive the investigational drug combined with Keytruda (pembrolizumab), and the other group would receive MIV-818 in combination with Lenvima (lenvatinib). The first phase of the trial is expected to identify a recommended a phase 2 dose. Once that has been identified, more groups of up to 30 patients will be enrolled into another phase of the trial.

The release noted that the first patient is expected to be enrolled onto the trial in the second half of 2021.

The protocol of a phase 2 trial has been amended to include an additional group of patients whose disease failed to respond to prior treatment with checkpoint inhibitors.

The VERSATILE-002 trial initially was opened to patients with checkpoint inhibitor-naive HPV16-associated head and neck cancer. Patients were being recruited to receive the investigational drug PDS0101 combined with Keytruda rather than chemotherapy as their first-line treatment for recurrent disease.

The study expanded to include a new group of patients which helps the researchers evaluate responses to the combination in approximately 40 patients with advanced disease who did not achieve a response to multiple treatments, including checkpoint inhibitors.

“There is an enormous unmet medical need in advanced head and neck cancer patients who have failed multiple therapies, including chemotherapy, radiation and checkpoint inhibitor therapy,” said PDS Biotech’s Chief Medical Officer Dr. Lauren Wood in a news release.

ImCheck Therapeutics recently announced that the first patient in the United States has been dosed as a part of the company’s EVICTION clinical trial assessing the investigational therapy ICT01 as a monotherapy or in combination with anti-PD-1 inhibitors in patients with solid and hematologic malignancies.

The EVICTION trial is a basket trial designed to evaluate the preliminary safety and efficacy of the therapy as a single-agent or in combination. Patients with bladder, breast, colorectal, gastric, melanoma, ovarian, prostate and pancreatic cancer are enrolled onto the trial. Moreover, patients with acute myeloid leukemia, acute lymphoblastic leukemia, follicular lymphoma, diffuse large B-cell lymphoma and non-small cell lung cancer also make up the study participants.

“Current immunotherapies are proving to be beneficial for patients with some cancers, but we need new approaches and treatments to extend these advances to more patients,” Dr. Patricia LoRusso, the associate center director for innovative medicine at the Yale University Cancer Center and an investigator in the EVICTION trial, said in a news release. “I believe the gamma9 delta2 T-cell activation seen to date with ICT01 has great potential ….”

The clinical trial sites in the United States include Yale University Cancer Center, Moffitt Cancer Center and the University of Washington/Seattle Cancer Care Alliance.

For more news on cancer updates, research and education, don’t forget to

Articles

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

CURE’s Clinical Trial Corner: June 2021

The first patient has been dosed in a phase 3 study evaluating the safety and efficacy of adding Monjuvi (tafasitamab-cxix) and lenalidomide to the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as a first-line treatment in high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL), according to a news release from Incyte and MorphoSys AG.

“While more than half of DLBCL patients can be cured with an aggressive chemotherapy regimen, current outcomes for high-risk patients are poor,” said MorphoSys’s Head of Global Drug Development Dr. Mike Akimov in the release. “We believe we may be able to make a difference for those DLBCL patients by adding the combination of (Monjuvi) and lenalidomide to R-CHOP, a current standard of care.”

Although R-CHOP is considered a standard-of-care for this patient population, approximately 40% of patients either fail to achieve a response or relapse after treatment, according to the release.

Of note, the Food and Drug Administration in 2020 approved Monjuvi plus lenalidomide to treat adults with relapsed/refractory DLBLC who were ineligible for receiving an autologous stem cell transplant. Shortly after that approval was announced, an expert spoke with 

G1 Therapeutics recently announced that patient enrollment was underway for a phase 2 study assessing the second- and third-line treatment of Cosela (trilaciclib) prior to the administration of the chemotherapy docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who had previously received treatment with a checkpoint inhibitor of chemotherapy.

“(NSCLC) is the most common type of lung cancer, accounting for nearly 85% of all diagnoses, and remains a great unmet medical need,” said Dr. Raj Malik, chief medical officer at G1 Therapeutics, in a news release. “Despite improvements in therapy for metastatic NSCLC, including the use of PD-1 or PD-L1 inhibitors, the majority of patients ultimately progress during or after treatment with immunotherapy and chemotherapy. In addition to the need for therapies that more effectively extend overall survival, patients treated in the metastatic setting are particularly vulnerable to chemotherapy-induced myelosuppression and health-related quality of life impacts associated with systemic chemotherapy.”

Approximately 146 patients are expected to be enrolled onto the study. The main goal of the trial, according to the release, is to evaluate the overall survival improvement with Cosela compared to placebo. Other goals include measuring progression-free survival benefit, overall response rate and duration of response.

Context Therapeutics and Jefferson Health’s Sidney Kimmel Cancer Center recently announced the dosing of the first patient in a phase 2 study assessing the effect of adding onapristone extended release to the hormone-based chemotherapy anastrozole in patients with metastatic endometrial cancer who previously failed treatment.

“The majority of endometrial cancer patients have hormone-driven cancer. Both estrogen and progesterone drive progression in those patients, and antiestrogens, most often anastrozole, have proven, albeit limited, activity,” said Dr. Russell Schilder, a co-principal investigator and director of the Gynecologic Medical Oncology Program at Sidney Kimmel Cancer Center, in a news release. “We will evaluate whether combining anastrozole with (onapristone extended release) will achieve more complete hormone blockade compared with anastrozole alone, which may lead to better outcomes for patients.”

Measuring the overall response rate (defined as proportion of patients who experience a partial or complete response to therapy) to the study treatment is the main goal of the study. The aim, according to the release, is to enroll approximately 25 patients who express the estrogen receptor and/or progesterone receptor biomarker. Additional goals of the study are to measure duration of response and progression-free survival.

Aspira Women’s Health and The Feinstein Institutes for Medical Research recently announced the two will begin a study to aid in the monitoring of women with benign adnexal masses — growths that occurs in or near the uterus, ovaries, fallopian tubes, and the connecting tissues — and detection of early-stage ovarian cancer.

“This study is two-fold, one is to vastly increase our enrollment to clinically validate the serial monitoring aspect OVASight test for all women who present with a mass and hereditary breast and ovarian cancer syndrome, and second, enrich our research and innovation pipeline,” said Aspira Women’s Health Chief Scientific Officer Lesley Northrop in a news release. “I am incredibly excited to work with the Feinstein Institutes in enhancing our biobank of biological samples and clinical data metrics. This will allow us the ability to evaluate additional biomarkers including ctDNA, RNA and proteins to apply as a multi-modal approach in early diagnosis of ovarian cancer as a liquid-biopsy based test.”

The aim is to enroll more than 600 women with adnexal masses, as well as more than 2,000 women considered at high risk for developing ovarian cancer.

One of the goals of the study, according to the release, is identify additional genomic markers to help develop a specific test for the early detection of ovarian cancer.

“Having testing options for women with benign masses to monitor them over time, as well as having a solution for assessing risk in high-risk women will provide meaningful insights for providers treating these women,” said Dr. Elena Ratner, a gynecologic oncologist and global chief medical advisor, clinical and translational medicine at Aspira Women’s Health, in the release.

CURE’s Clinical Trial Corner: May 2021

Sirtex Medical recently announced that the Food and Drug Administration (FDA) approved the DOORwaY90 trial, which aims to assess the safety and efficacy of selective internal radiation therapy (SIRT) using the company’s SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma.

The SIRT with SIR-Spheres® Y-90 resin microspheres, according to a news release from Sirtex, is a prescription device for the treatment of inoperable liver tumors which delivers high doses of high-energy beta radiation directly to the tumors. Interventional radiologists administer the therapy via a catheter into the liver arteries that supply blood to the tumors. The procedure aims to target the cancer cells, while sparing healthy tissue.

“Our therapy is used for treatment in HCC in more than 50 countries, with years of safety and efficacy,” Sirtex’s CEO Kevin Smith said in the release. “The DOORwaY90 Study has the potential to expand the FDA-approved indication for use of SIR-Spheres in the U.S., which would mark an incredible achievement in patient care.”

The single-arm study is expected to enroll 100 patients across 15 cancer centers in the United States. The study population is expected to consist of patients with stage a, b1 and b2 disease who are ineligible for resection or ablation.

The first patient has been dosed in a phase 2 study evaluating the safety and efficacy of Pvsripo alone or combined with a programmed cell death protein-1/ligand 1 (PD-1/L1) inhibitor in patients with melanoma who are resistant to these therapies, according to a news release from the agent’s manufacturer, Istari Oncology.

Pvsripo is a viral immunotherapy that activates the innate and adaptive immune system to stimulate the production of a functional, systemic anticancer CD8-positive T-cell responses, according to the release.

The open-label, phase 2, multicenter randomized LUMINOS-102 trial is expected to evaluate objective response rates, durability of responses, progression-free survival and overall survival over a 24-month period. An interim analysis is planned once the trial has accrued 20 patients and they have been treated for three months.

“Being based on the poliovirus vaccine, our team was intrigued by the potential for Pvsripo to leverage an immunological recall response to fight cancer in patients who have been vaccinated against polio. This and other unique mechanisms as well as the responses seen in the phase 1 trial encouraged us to get involved in LUMINOS-102,” Dr. Ding Wang, director of the phase 1 program and associate director of Clinical Trials Office at Henry Ford Cancer Institute in Detroit, said in the release. “LUMINOS-102 will build on these data and further evaluate the ability of Pvsripo to generate a systemic immune response, important for patients with unresectable anti–PD-1 refractory melanoma. We’re proud to be the first site to treat a participant and looking forward to continuing enrollment.”

The trial is expected to be conducted across more than 20 cancer centers in the United States, including the Henry Ford Cancer Institute.

The first patient has been dosed in a study aimed at assessing the benefit of interleukin-7 (IL-7) in patients with cancer who have contracted COVID-19, the Cancer Research Institute announced.

The phase 2 multi-center trial, known as ILIAD-7US-O, is expected to review the benefit of RevImmune’s CYT107 in approximately 48 patients with cancer. The trial, according to a news release, would be the first to test an IL-7 drug in those with cancer who also have COVID-19.

“This partnership allows (Cancer Research Institute) to apply RevImmune’s promising IL-7 agent in a novel setting of patients with both cancer and COVID-19, potentially offering a way to strengthen the immune system’s ability to fend off the SARS-CoV-2 coronavirus, mitigate symptoms of COVID-19, and improve overall outcomes for people living with cancer and COVID,” Jay Campbell, the managing director of Cancer Research Institute’s Venture Fund and Anna-Maria Kellen Clinical Accelerator, in a news release.

The Ivy Brain Tumor Center recently announced the dosing of its first patient in a phase 0 trial of a noninvasive drug-device combination for patients with recurrent glioblastoma and other high-grade gliomas.

The first-in-patient trial aims to assess sonodynamic therapy using a magnetic resonance-guided focused ultrasound technology in combination with a novel therapy, according to a news release.

“This novel modality may prove to be an indispensable new tool for patients, families and physicians racing against what is often a fatal disease and one that has not seen an FDA-approved drug in decades,” Shwetal Mehta, deputy director and chief operating officer of the Ivy Brain Tumor Center, said in the release. “The noninvasive aspect of this treatment is particularly unique, as we are always looking to preserve patient quality of life while aggressively treating such tumors.”

Here is a list of some recent trials that launched within the cancer space in April.

CURE’s Clinical Trial Corner: April 2021

Compugen Ltd. recently announced the expansion of a collaboration agreement with Bristol Myers Squibb. The expanded agreement allows Compugen to add Bristol Myers Squibb’s Opdivo (nivolumab) to COM701 — a first-in-class anti-PVRIG antibody — in patients with select cancer indications enrolled onto a phase 1b combination study.

“We are excited to further expand our clinical program evaluating COM701,” Compugen’s president and CEO Anat Cohen-Dayag said in a news release. "While our triple checkpoint blockade study of COM701 combined with Bristol Myers Squibb's PD-1 and TIGIT inhibitors currently advancing in the clinic offers the ultimate test of our science-driven hypothesis, translational research at Compugen suggests that certain patients may not require a triple therapy combination. With the enrollment in the dose escalation arm of COM701 in combination with Opdivo completed and preliminary signs of antitumor activity previously disclosed, we are ready to continue our evaluation of this dual combination and move to the cohort expansion phase of the study.”

The phase 1b study (NCT03667716) is expected to analyze fixed doses of COM701 and Opdivo in patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers.

Aileron Therapeutics recently announced it plans to expand the enrollment target for an upcoming phase 1b trial of a novel therapy in patients with non-small cell lung cancer.

The trial, which had an original target enrollment of 40 patients, is now expected to enroll 60 patients with advanced p53-mutated non-small cell lung cancer who are undergoing treatment with first-line chemotherapies carboplatin plus pemetrexed. The aim of the study is to assess if ALRN-6924 — a chemoprotective agent — can reduce or eliminate chemotherapy-induced side effects without diminishing the chemotherapy’s ability to kill the cancer cells.

“Last month, the field of chemoprotection took a giant step forward with 

the approval of the industry’s first chemoprotection agent

, which is approved to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive small-cell lung cancer,” Dr. Manuel Aivado, president and CEO of Aileron, said in a news release. “With this milestone, the regulatory path for chemoprotective agents like ALRN-6924 has now been clarified. ALRN-6924 is the first and only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. This strategy is designed to selectively protect healthy cells in the body from chemotherapy while ensuring we do not protect cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells.”

Aileron announced it expects to enroll patients onto the trial in the second quarter of 2021.

The first patient has been dosed in a phase 1/2 trial of KB-0742 — an oral bioavailable cyclin dependent kinase 9 (CDK9) inhibitor — to treat MYC-amplified solid tumors, Kronos Bio announced.

Kronos expects to enroll approximately 100 patients with advanced solid tumors or non-Hodgkin lymphoma onto to open-label trial. The trial is expected to consist of a dose-escalation stage — to review safety and set a recommended dose. The expansion stage, according to Kronos, is then expected to study that dose further in patients.

“KB-0742 represents a promising new approach to treating cancers that are transcriptionally addicted to MYC. We are excited to have initiated our clinical development program for KB-0742, which emerged from our internal discovery research efforts and moved quickly into clinical testing in under two years,” Norbert Bischofberger, president and CEO of Kronos, said in a news release. “We believe KB-0742 has the potential to be a meaningful advance in the treatment of MYC-amplified cancers, which represent approximately 30% of solid tumors.”

The company expects to report initial data from the dose-escalation study in the fourth quarter of 2021.

The institutional review board of Roswell Park Comprehensive Cancer Center in Buffalo, New York has approved an amendment which called for the randomization of an additional 20 patients into a phase 1/2a study evaluating a two-drug combination for the treatment of patients with cancer and mild-to-moderate COVID-19 infection.

In November 2020, AIM ImmunoTech announced that the first patient had been enrolled and received treatment with Ampligen (rintatolimod) and interferon alpha-2b to combat mild-to-moderate COVID-19.

“We are excited to see Ampligen tested not only as part of an antiviral treatment combination for COVID-19 among cancer patients, but also as a possible standalone therapy for this terrible virus,” AIM president and CEO Thomas K. Equels said in a news release. “An early-onset treatment is especially critical for cancer patients, who face significantly increased risk of severe symptoms or death.”

Here is a list of some recent trials that launched within the cancer space in March.

CURE’s Clinical Trial Corner: March 2021

Bayer and Orion Corporation recently announced the launch of a new phase 3 study to investigate the safety and efficacy of Nubeqa (darolutamide) plus androgen deprivation therapy versus placebo plus androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

“Nubeqa has already shown in men with non-metastatic castration-resistant prostate cancer that it extends metastasis-free and overall survival,” Dr. Scott Z. Fields, senior vice president and head of Oncology Development at Bayer's Pharmaceutical Division, said in a company-issued press release. “Given the encouraging results that we have seen with Nubeqa so far, it is important that we also evaluate the potential of Nubeqa in other stages of prostate cancer that may offer men with (metastatic hormone-sensitive prostate cancer) a new treatment option.”

The new randomized, double-blind, placebo-controlled trial (ARANOTE) is expected to enroll 555 men. The main goal of the study, according to the release, is to assess radiological progression-free survival (the time from treatment to disease progression or worsening).

Cartesian Therapeutics recently announced the beginning of a phase 2a trial assessing Descartes-11 (an mRNA CAR-T cell therapy) in patients with newly diagnosed, high-risk multiple myeloma.

The manufacturer anticipates enrolling 30 patients with newly diagnosed, high-risk myeloma across multiple cancer centers in the United States. The goal of the study, according to the release, is to assess the safety and early efficacy of the CAR-T cell therapy in patients who have completed a pre-transplant anti-myeloma drug combination regimen but still have residual disease.

“Patients newly diagnosed with high-risk multiple myeloma seldom achieve deep, durable responses after frontline therapy,” Dr. Kenneth Anderson, Kraft Family Professor of Medicine at Harvard Medical School and Program Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, said in a company-issued press release. “Integrating a CAR-T cell therapy into our standard of care, without using lymphodepleting chemotherapy, would be a welcome addition to our toolkit for treating this currently incurable disease.”

Rutgers Cancer Institute of New Jersey has treated its first patient with upper tract urothelial cancer with a recently approved treatment option.

“It’s important to understand the indications for this drug, so visiting a center with expertise in (upper tract urothelial cancer) is essential,” Dr. Saum Ghodoussipour, director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute, said in a press release. “While (Jelmyto) gives patients a good non-surgical option, it’s not necessarily for every patient and if there is recurrence after the treatment, the management of (upper tract urothelial cancer) can be complex, requiring multidisciplinary care from urologists, medical oncologists, pathologists and radiologists.”

The Addario Lung Cancer Medical Institute and GO2 Foundation for Lung Cancer recently announced the start of a new study to assess the underlying causes of lung cancer diagnoses in people under the age of 40.

The Epidemiology of Young Lung Cancer study aims to survey 250 patients who were diagnosed before they turned 40. The confidential survey will ask questions about a patient’s medical history, demographics, environmental exposures and other lifestyle questions. Participants are also going to be asked to provide a blood sample for further study.

“Patients hold the key to research. Now that we have confirmed that young lung cancer looks different than other lung cancer, discovering the how and why of it through epidemiology will be critical to our ongoing efforts to prevent, diagnose early, and more effectively treat lung cancer in young patients,” Bonnie J. Addario, GO2 Foundation co-founder, board chair, and stage 3b lung cancer survivor, said in a release. “What we learn from young lung cancer will also help unlock answers for the entire lung cancer community.”

Here is a list of some recent trials that launched within the cancer space in February.

CURE’s Clinical Trial Corner: February 2021

The first patient has been dosed in an ongoing phase 1/2 trial of HPN328, an investigational therapy, for the treatment of patients with small cell lung cancer and other tumors associated with expression of delta like ligand 3, a protein highly expressed in certain tumors.

“Treatment options for small cell lung cancer are limited, as are options for other DLL3-associated tumors such as neuroendocrine prostate cancer,” Harpoon Therapeutics’ chief medical officer Dr. Natalie Stacks said in a company-issued press release. “Data from preclinical studies suggest that HPN328 has substantial anti-tumor activity, which provides the rationale for investigating its potential benefit in these patients.”

The aim of the open-label study is to assess the safety, tolerability and pharmacokinetics (how a drug is absorbed and released from the body) of HPN328. Patients with small cell lung cancer whose disease has relapsed after received at least one prior line of platinum-based chemotherapy are expected to be enrolled in the study.

“We are excited to participate in this trial of a promising agent that will hopefully benefit patients with small cell lung cancer and other neuroendocrine tumors,” Dr. Melissa Johnson, program director of lung cancer research at Sarah Cannon Research Institute, said in the release.

The first patient was treated at Sarah Cannon Research Institute at Tennessee Oncology.

Kintara Therapeutics recently announced that patient recruitment for a registrational phase 2/3 clinical trial for glioblastoma has begun.

The goal of the trial – Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) – is to evaluate the safety and efficacy of VAL-083 in those with recurrent or newly-diagnosed glioblastoma.

"The entire Kintara team is grateful and excited to participate in (Global Coalition for Adaptive Research)'s groundbreaking GBM AGILE study as it offers an extraordinary opportunity to facilitate the advancement of VAL-083's clinical development in a premier (glioblastoma) study," Kintara’s CEO Saiid Zarrabian said in a press release. "This is truly an important milestone for Kintara as we believe the study will generate important insights into the breadth of VAL-083's potential to address this deadliest form of brain cancer in all patient subtypes, while potentially bringing the program to the doorstep of commercialization."

The first patient has been dosed in the dose-expansion cohort of a phase 1 trial of STRO-002 for the treatment of patients with ovarian cancer, according to the agent’s manufacturer, Sutro Biopharma.

"STRO-002 continues to be well-tolerated and we have observed encouraging preliminary activity in patients with advanced platinum-resistant and refractory ovarian cancer,” Dr. Lainie Martin, leader of the gynecology/oncology program at Hospital of the University of Pennsylvania, said in a company-issued press release. “We are excited to be part of the STRO-002-GM1 dose-expansion study and to provide additional clinical data to show the potential of this therapeutic for ovarian patients with limited treatment options."

The cohort currently enrolling includes patients with ovarian cancer with platinum-resistant disease who have previously received from one to three therapies, or platinum-sensitive patients who have received two to three previous treatments.

IDEAYA Biosciences recently announced the first patient was dosed in a phase 1 combination study of IDE196 and Xalkori (crizotinib) in metastatic uveal melanoma (a rare form of eye cancer).

"IDEAYA's clinical trials evaluating IDE196 plus either (Xalkori) or (Mektovi) as combination therapies are each based on compelling biological rationale for treating patients with metastatic uveal melanoma – a solid tumor for which there is a high unmet medical need and currently no approved therapies,” said Dr. Meredith McKean, associate director of the Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology, in a company-issued press release.

In this study, IDEAYA is collaborating with Pfizer (the manufacturer of Xalkori) in an attempt to evaluate the combination.

Here is a list of some recent trials that launched within the cancer space in January.

Clinical Trial Corner

CURE’s Clinical Trial Corner: June 2021

CURE’s Clinical Trial Corner: May 2021

CURE’s Clinical Trial Corner: April 2021

CURE’s Clinical Trial Corner: March 2021

CURE’s Clinical Trial Corner: February 2021

CURE’s Clinical Trial Corner: January 2021

Latest News